Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 145–151 of 151
The DAC Egypt Cohort is a longitudinal study designed to identify early biomarkers and risk factors for Alzheimer's disease in an understudied Egyptian population, addressing a critical gap in dementia research outside Western cohorts. Early detection and prevention strategies depend on understanding how disease processes vary across genetic and environmental contexts.
Technogym and Google Cloud are integrating generative AI into fitness platforms to shift from episodic workout protocols toward continuous, anticipatory health management scaled across populations. This partnership pairs four decades of physiological performance data with advanced language models to support adherence—a persistent barrier to preventive health outcomes—while embedding technology into the daily behavioral substrate where health decisions actually occur.
Eli Lilly's $2.75 billion partnership with Insilico Medicine represents a strategic pivot toward AI-driven drug discovery aimed at aging-related pathology beyond current GLP-1 applications. The deal signals that large pharmaceutical companies now view longevity therapeutics as a commercially serious category worthy of substantial investment in discovery infrastructure.
Plasma proteomic analysis of Swiss centenarians identifies a distinct protein signature associated with preserved youthfulness and longevity. This proteomic fingerprint offers a measurable biomarker set for aging trajectories and potential intervention targets.
Lifetime cognitive enrichment from childhood through late life is associated with a 38% reduced dementia risk and delays cognitive decline by 5–7 years. The protective effect accumulates across all life stages, with late-life engagement showing the strongest individual contribution to risk reduction.
Stanford-led THRIVE coalition secured $34.5 million to develop the first FDA-grade Intrinsic Capacity score, a composite measure integrating wearables, blood biomarkers, and functional assessments to predict 20-year health outcomes. This addresses the field's critical gap: the absence of regulatory-grade measurement infrastructure for aging itself, moving beyond disease-specific endpoints toward quantifiable functional decline.
Seveno Capital's investment in PointFit reflects a market shift toward direct biochemical monitoring via wearable patches that measure lactate and other sweat biomarkers in real time. Continuous metabolic substrate tracking—rather than behavioral proxies like step count—provides actionable insight into energy dynamics, recovery debt, and metabolic flexibility relevant to both performance optimization and early detection of metabolic decline.
